Patents by Inventor Yukako Fujinaga
Yukako Fujinaga has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11795438Abstract: Provided are a method for promoting the proliferation of pluripotent stem cells and a proliferation promoting composition used in the method. In one aspect, a composition for promoting the proliferation of pluripotent stem cells includes hemagglutinin or modified hemagglutinin. In another aspect, a method for promoting the proliferation of pluripotent stem cells includes culturing pluripotent stem cells in a culture medium to which the proliferation promoting composition of the present disclosure has been added.Type: GrantFiled: December 19, 2017Date of Patent: October 24, 2023Assignee: Osaka UniversityInventors: Masahiro Kinooka, Meehae Kim, Yukako Fujinaga
-
Patent number: 11230701Abstract: Provided are a novel hemagglutinin that can remove cells deviated from the undifferentiated state, the cells being cells that emerge in a colony during culture of stem cells having pluripotency, and a novel method for culturing stem cells having pluripotency, the method using hemagglutinin. Provided is a mutant hemagglutinin complex protein derived from Clostridium botulinum type B, the complex protein containing at least subcomponents HA2 and HA3 of hemagglutinin derived from Clostridium botulinum type B, and the complex protein containing amino acids constituting a glycosylation site, with at least one of the amino acids having been mutated. Provided is a method for culturing stem cells having pluripotency, the method including culturing the stem cell having pluriopotency in the presence of a mutant hemagglutinin complex protein of the present disclosure.Type: GrantFiled: June 29, 2015Date of Patent: January 25, 2022Assignee: Osaka UniversityInventors: Masahiro Kinooka, Meehae Kim, Yukako Fujinaga, Yo Sugawara
-
Publication number: 20210122790Abstract: The present invention provides a miniaturized hemagglutinin complex protein having function inhibitory activity against E-cadherin, wherein (a) all or a part of at least HA1 subcomponent, and/or a part of HA3 subcomponent are/is deleted, (b) regions in HA2 and HA3 subcomponents that contribute to binding with E-cadherin are present, and (c) the HA3 subcomponent is derived from Clostridium botulinum type A or type B, and an E-cadherin function inhibitor containing the hemagglutinin complex protein.Type: ApplicationFiled: November 22, 2018Publication date: April 29, 2021Applicants: NATIONAL UNIVERSITY CORPORATION KANAZAWA UNIVERSITY, OSAKA UNIVERSITYInventors: Yukako FUJINAGA, Sho AMATSU, Masahiro KINOOKA
-
Publication number: 20200017836Abstract: Provided are a method for promoting the proliferation of pluripotent stem cells and a proliferation promoting composition used in the method. In one aspect, a composition for promoting the proliferation of pluripotent stem cells includes hemagglutinin or modified hemagglutinin. In another aspect, a method for promoting the proliferation of pluripotent stem cells includes culturing pluripotent stem cells in a culture medium to which the proliferation promoting composition of the present disclosure has been added.Type: ApplicationFiled: December 19, 2017Publication date: January 16, 2020Applicant: Osaka UniversityInventors: Masahiro Kinooka, Meehae Kim, Yukako Fujinaga
-
Patent number: 10226529Abstract: An object of the present invention is to provide an adjuvant for a mucosal vaccine with high safety that induces a sufficient immune response in a mucosal membrane. According to the present invention, an adjuvant for a mucosal vaccine containing a protein complex composed of hemagglutinin (HA) subcomponents HA1 and HA2, and mutant subcomponent HA3 of botulinum toxin is provided.Type: GrantFiled: June 2, 2015Date of Patent: March 12, 2019Assignee: Osaka UniversityInventors: Nao Jonai, Yukako Fujinaga, Masahiro Yutani, Yo Sugawara, Takuhiro Matsumura
-
Patent number: 9822344Abstract: Provided is a method by which cells deviated from the undifferentiated state, which emerge in a colony during culture of stem cells having pluripotency, can be removed. In one aspect, provided is a method for culturing stem cells having pluripotency, the method including performing cell culture in the presence of a substance that can inhibit cell-cell adhesion. In another aspect, provided is a method for removing cells deviated from the undifferentiated state, the cells being cells that have emerged or may possibly emerge during culture of stem cells having pluripotency, the method including performing cell culture in the presence of a substance that can inhibit cell-cell adhesion. In still another aspect, provided is a method for maintaining the undifferentiated state of stem cells having pluripotency, the method including performing cell culture in the presence of a substance that can inhibit cell-cell adhesion.Type: GrantFiled: December 26, 2013Date of Patent: November 21, 2017Assignee: Osaka UniversityInventors: Masahiro Kinooka, Meehae Kim, Yukako Fujinaga, Yo Sugawara
-
Publication number: 20170196970Abstract: An object of the present invention is to provide an adjuvant for a mucosal vaccine with high safety that induces a sufficient immune response in a mucosal membrane. According to the present invention, an adjuvant for a mucosal vaccine containing a protein complex composed of hemagglutinin (HA) subcomponents HA1 and HA2, and mutant subcomponent HA3 of botulinum toxin is provided.Type: ApplicationFiled: June 2, 2015Publication date: July 13, 2017Applicant: OSAKA UNIVERSITYInventors: Nao Jonai, Yukako Fujinaga, Masahiro Yutani, Yo Sugawara, Takuhiro Matsumura
-
Patent number: 9662386Abstract: An object of the present invention is to provide an adjuvant for a mucosal vaccine with high safety that induces a sufficient immune response on the mucosa. According to the present invention, an adjuvant for a mucosal vaccine comprising a protein complex composed of hemagglutinin (HA) subcomponents HA1, HA2, and HA3 of botulinum toxin is provided.Type: GrantFiled: July 29, 2016Date of Patent: May 30, 2017Assignee: Osaka UniversityInventors: Yukako Fujinaga, Takuhiro Matsumura, Masahiro Yutani, Nao Jonai
-
Publication number: 20170130206Abstract: Provided are a novel hemagglutinin that can remove cells deviated from the undifferentiated state, the cells being cells that emerge in a colony during culture of stem cells having pluripotency, and a novel method for culturing stem cells having pluripotency, the method using hemagglutinin. Provided is a mutant hemagglutinin complex protein derived from Clostridium botulinum type B, the complex protein containing at least subcomponents HA2 and HA3 of hemagglutinin derived from Clostridium botulinum type B, and the complex protein containing amino acids constituting a glycosylation site, with at least one of the amino acids having been mutated. Provided is a method for culturing stem cells having pluripotency, the method including culturing the stem cell having pluriopotency in the presence of a mutant hemagglutinin complex protein of the present disclosure.Type: ApplicationFiled: June 29, 2015Publication date: May 11, 2017Applicant: Osaka UniversityInventors: Masahiro Kinooka, Meehae Kim, Yukako Fujinaga, Yo Sugawara
-
Publication number: 20160324960Abstract: An object of the present invention is to provide an adjuvant for a mucosal vaccine with high safety that induces a sufficient immune response on the mucosa. According to the present invention, an adjuvant for a mucosal vaccine comprising a protein complex composed of hemagglutinin (HA) subcomponents HA1, HA2, and HA3 of botulinum toxin is provided.Type: ApplicationFiled: July 29, 2016Publication date: November 10, 2016Applicants: DAIICHI SANKYO COMPANY, LIMITED, OSAKA UNIVERSITYInventors: Yukako Fujinaga, Takuhiro Matsumura, Masahiro Yutani, Nao Jonai
-
Publication number: 20150329831Abstract: Provided is a method by which cells deviated from the undifferentiated state, which emerge in a colony during culture of stem cells having pluripotency, can be removed. In one aspect, provided is a method for culturing stem cells having pluripotency, the method including performing cell culture in the presence of a substance that can inhibit cell-cell adhesion. In another aspect, provided is a method for removing cells deviated from the undifferentiated state, the cells being cells that have emerged or may possibly emerge during culture of stem cells having pluripotency, the method including performing cell culture in the presence of a substance that can inhibit cell-cell adhesion. In still another aspect, provided is a method for maintaining the undifferentiated state of stem cells having pluripotency, the method including performing cell culture in the presence of a substance that can inhibit cell-cell adhesion.Type: ApplicationFiled: December 26, 2013Publication date: November 19, 2015Applicant: OSAKA UNIVERSITYInventors: Masahiro Kinooka, Meehae Kim, Yukako Fujinaga, Yo Sugawara
-
Publication number: 20150306214Abstract: An object of the present invention is to provide an adjuvant for a mucosal vaccine with high safety that induces a sufficient immune response on the mucosa. According to the present invention, an adjuvant for a mucosal vaccine comprising a protein complex composed of hemagglutinin (HA) subcomponents HA1, HA2, and HA3 of botulinum toxin is provided.Type: ApplicationFiled: November 15, 2013Publication date: October 29, 2015Applicants: DAIICHI SANKYO COMPANY LIMITED, OSAKA UNIVERSITYInventors: Yukako Fujinaga, Takuhiro Matsumura, Masahiro Yutani, Nao Jonai